Acusphere promotes Walovitch to senior VP, clinical research

Dec. 14, 2005 — Acusphere Inc. (NASDAQ: ACUS), a Watertown, Mass.-based specialty pharmaceutical company that develops new drugs and improved formulations of existing drugs using its proprietary microparticle technology, announced that Rick Walovitch has been promoted to senior vice president of clinical research, effective immediately. Walovitch has served as vice president of clinical research at Acusphere since 1997.

During his tenure at Acusphere, Walovitch has directed all functions of Acusphere’s clinical operations and is responsible for developing and implementing the clinical strategy for AI-700, currently in Phase 3 clinical trials.


Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.